VKTX · Viking Therapeutics Inc
United States · RS rating 28 · As of 2026-11-03
| Price | 26.09 USD |
|---|---|
| 1-day change | -2.8% |
| RS rating (overall / 1M / 3M / 12M) | 28 / 34 / 29 / 30 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 6 / 19 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -70.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +38.1% |
| Market cap (USD) | $3.8B |